Olivier Arsène

Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study

Caroline Charlier, Élodie Perrodeau, Alexandre Leclercq et al. · The Lancet Infectious Diseases · 2017 · 577 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +12

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial

Jacobus Pfisterer, Catherine Shannon, Klaus Baumann et al. · The Lancet Oncology · 2020 · 162 citations

Medicine, Gynecology, Oncology +14

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Xavier Pivot, Gilles Romieu, Marc Debled et al. · The Lancet · 2019 · 128 citations

Medicine, Oncology, Breast Oncology +9

Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study

Elisé G. Kaboré, Charles Guénancia, Inês Vaz-Luís et al. · PLoS Medicine · 2019 · 73 citations · Full text

Medicine, Oncology, Pharmacology +17

Abstract GS3-05: Fulvestrant-palbociclib vs continuing aromatase inhibitor-palbociclib upon detection of circulating <i>ESR1</i> mutation in HR+ HER2- metastatic breast cancer patients: Results of PADA-1, a UCBG-GINECO randomized phase 3 trial

François‐Clément Bidard, Anne‐Claire Hardy‐Bessard, Thomas Bachelot et al. · Cancer Research · 2022 · 31 citations

Medicine, Oncology, Pharmacology +15